Home › Funds › GMO › GMO Benchmark-Free Fund
Fund family: GMO · Filed by GMO TRUST (CIK 772129) · SEC series S000033464
Ticker: GBFFX (C000102896)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 10,895 with, 259 against, 45 abstentions (not counted as with management); 236 items carried no recommendation; 1 split votes are in neither count. Shareholder proposals: 102 FOR, 214 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as GMO’s manager page (51,210 ballot items across 26 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | GMO | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 90.6% | 9,060 | 91.3% | 40,970 |
| Backed environmental and social shareholder proposals at US companies | 9.3% | 54 | 10.3% | 369 |
Each ballot item this fund voted is set against the votes of the other GMO funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most GMO funds on all 4,923 items where a comparison was possible.
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 5,708 | 30 |
| Corporate Governance | 2,045 | 102 |
| Capital Structure | 1,374 | 13 |
| Compensation | 1,266 | 21 |
| Audit-related | 620 | 0 |
| Say-on-Pay | 120 | 0 |
| Other | 82 | 0 |
| Extraordinary Transactions | 77 | 1 |
| Other Social Issues | 59 | 24 |
| Environment or Climate | 52 | 51 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Rio Tinto Plc | May 6, 2026 | $4M | 21 | 0 |
| Target Corporation | June 10, 2026 | $3M | 18 | 3 |
| Pfizer Inc. | April 23, 2026 | $3M | 16 | 1 |
| Verizon Communications Inc. | May 21, 2026 | $3M | 15 | 3 |
| General Motors Company | June 2, 2026 | $3M | 17 | 2 |
| Citigroup Inc. | May 20, 2026 | $3M | 16 | 0 |
| Regeneron Pharmaceuticals, Inc. | June 12, 2026 | $3M | 7 | 0 |
| Johnson & Johnson | April 23, 2026 | $3M | 15 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| June 10, 2026 | Target Corporation | Shareholder proposal requesting policy requiring the Board Chair to be an independent director. Shareholder proposal | For | Against |
| June 10, 2026 | Target Corporation | Shareholder proposal requesting a report on presence of pesticides in Target's private label brands. Shareholder proposal | For | Against |
| April 23, 2026 | Pfizer Inc. | Adopt an Independent Chair Policy Shareholder proposal | Against | For |
| May 21, 2026 | Verizon Communications Inc. | Board oversight of material issues related to climate change Shareholder proposal | Against | For |
| May 21, 2026 | Verizon Communications Inc. | Independent board chair Shareholder proposal | Against | For |
| June 2, 2026 | General Motors Company | Shareholder Proposal Regarding Separation of Chair and CEO Roles Shareholder proposal | Against | For |
| June 2, 2026 | General Motors Company | Shareholder Proposal Requesting a Report on Human Rights Standards for Indigenous Peoples Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| March 17, 2026 | QUALCOMM Incorporated | Stockholder proposal entitled "Shareholder Ability to Call for a Special Meeting." Shareholder proposal | For | Against |
| March 17, 2026 | QUALCOMM Incorporated | Stockholder proposal entitled "Report on Risk of China Exposure." Shareholder proposal | Against | For |
| April 22, 2026 | The Cigna Group | Shareholder Proposal - Shareholder Right to Act by Written Consent Shareholder proposal | Against | For |
| May 13, 2026 | Elevance Health, Inc. | Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposal | Against | For |
11,441 ballot items at 944 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, GMO Benchmark-Free Fund (GBFFX) voted at 944 shareholder meetings of 854 companies, on 11,441 ballot items in all. Where management made a recommendation, the fund followed it on 97.3% of the items and voted against it 259 times. Its most frequent area of disagreement was corporate governance (102 of its votes against management). It voted FOR 32.3% of the 316 shareholder proposals on which it cast a FOR or AGAINST vote. It voted FOR the board's own proposals less often than GMO's funds as a whole (90.6% against 91.3%). It voted the same way as most GMO funds on every item where a comparison was possible.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of GMO’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.